Hasten Biopharmaceutical Co. Ltd. has successfully completed Market Authorisation Transfers (MAT) for 11 pharmaceutical products across key Asia-Pacific markets, including Malaysia, Singapore, and Hong Kong.
This strategic move, executed by Hasten Biopharmaceutics Asia Co. Ltd. in the first half of 2025, aims to strengthen Hasten’s regional expansion and commitment to providing high-quality healthcare solutions.
The transferred products, which are well-established in treating chronic diseases such as cardiovascular conditions and diabetes, include Actos, Actosmet, Blopress, and Nesina, among others. Hasten plans to leverage its expertise in regulatory filing, manufacturing transfer, and marketing strategies to support its global biopharmaceutical partners in achieving their Asia-Pacific goals.
Honggang Feng, Chairman and CEO of Hasten, highlighted the significance of this achievement, stating, “The successful MAT transfers of multiple chronic disease products have significantly expanded Hasten’s portfolio in the Asia-Pacific region. This marks a key milestone in our globalisation journey and reinforces our commitments to delivering high-quality medicines.”
Peggy Fung, Vice President and Head of Asia-Pacific Commercial at Hasten, added, “Achieving MAT transfers across multiple markets in such a short time demonstrates Hasten’s strong alignment with international standards in areas such as regulatory supply chain, quality control, and commercialisation management.”
Hasten, established in 2020, continues to focus on high-demand therapeutics and aims to expand its product pipeline across Asia-Pacific. The company is committed to creating a healthcare ecosystem that benefits patients worldwide, supported by a dedicated regional team and strategic partnerships.
“`
